Aurobindo Pharma Ltd. Investor Presentation

Aurobindo Pharma Ltd. Investor Presentation: Get insights into company performance, financials, capex plans and more

announcement
Conference/Earnings Calls Alerts
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated November 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on November 14, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Second quarter and half year ended September 30, 2022. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Further to our letter dated September 6, 2022 informing about the participation in the Kotak Institutional Equity Healthcare Forum 2022 on September 8, 2022, we inform you that the presentation updated in the following weblink of the Company will be used during the interaction with the investors. https://www.aurobindo.com/wp-content/uploads/2022/09/Aurobindo-Pharma_Investor-Presentation_INR_Sep-22.pdf No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2022. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated February 3, 2022 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2021. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated November 2, 2021 wherein we have intimated the schedule of Investors/ Analysts call on November 9, 2021. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2021. The presentation is also being uploaded in the following weblink of the Company.
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated August 7, 2021 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2021. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2021. The presentation is also being uploaded in the following web-link of the Company.
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated May 28, 2021 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2021. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021. The presentation is also being uploaded in the following weblink of the Company.
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated February 9, 2021 wherein we have intimated the schedule of Investors/ Analysts call on February 11, 2021. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter ended December 31, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated November 10, 2020 wherein we have intimated the schedule of Investors/ Analysts call on November 12, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second Quarter ended September 30, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/

No results found